Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 1(4)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07550621Phase 1Not Yet Recruiting

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

Role: lead

NCT07550634Phase 1Not Yet Recruiting

Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment

Role: lead

NCT07274137Phase 3Not Yet Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）

Role: lead

NCT07110766Phase 1Not Yet Recruiting

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

Role: lead

NCT06778850Phase 1Recruiting

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants

Role: lead

NCT06606483Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Role: lead

All 6 trials loaded